Consistent with the trends in YTHDF1 and PKM2 expression, the tumor growth in the agomiR-16-5p treatment group was evidently inhibited, in which the average tumor volume after 24 days of administration was about 1/4 of that of the control group (Fig. 6G–I and Supplementary Fig. S6C, F; Original western blot data 15). Here, YTHDF1 is linked to neoplasm.